Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 in Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
NCT04002622Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2019; status: terminated.
02
Drugs
benmelstobart
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04002622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002622.